Duration of intravenous antibiotic therapy in people with cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 5, 2013, Pages

  Plummer, Amanda ^a   Wildman, Martin ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; DISEASE EXACERBATION; DRUG SAFETY; HUMAN; LUNG FIBROSIS; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; BACTERIAL INFECTIONS; COMPLICATION; CYSTIC FIBROSIS; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASES; LUNG DISEASE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAVENOUS; LUNG DISEASES;

EID: 84884246307     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006682.pub4     Document Type: Review

References (69)

1. Adeboyeku D, Jones AL, Hodson ME. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. Journal of Cystic Fibrosis 2011;10(1):25-30. [CFGD Register: PI250].
2. Hjelte L, Widen B, Malmborg AS, Freyschuss U, Strandvik B. Intravenous administration of antibiotics at home in patients with cystic fibrosis improves quality of life. Lakartidningen 1988;85(18):1614-7.
3. Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, et al.Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrobial Agents and Chemotherapy 2009;53(9):3650-6.
4. Kapranov NI, Belousov YB, Kashyrskaya NY, Smirnova EY. Quinoline therapy in children with cystic fibrosis [abstract]. Proceedings of 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium. 1995:P19.
5. Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, et al.Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrobial Agents and Chemotherapy 2011;55(7):3393-8. [CFGD Register: PI251].
6. Kenny S, Hall V, Goldsmith C, Moore J, Rendall JC, Elborn JS. Eradication of Pseudomonas aeruginosa in adults with CF [abstract]. Journal of Cystic Fibrosis 2009;8(Suppl 2):S39, Abstract no: 158.
7. Knight RK, Batten JC, Mearns M. A double blind trial of cephalexin in cystic fibrosis patients with pseudomonas in the sputum [abstract]. Proceedings of 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:52.
8. Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. Journal of Cystic Fibrosis 2008;7(2):142-6. [MEDLINE: 87210211].
9. Postnikov SS, Semykin SY, Polikarpova SV, Dubovik LG, Gracheva LA, Sagatelyan RM. A prospective trial on the efficacy and tolerability of twice-daily dosing (TDD) versus once-daily dosing (ODD) amikacin in cystic fibrosis patients [abstract]. Journal of Cystic Fibrosis 2007;6(Suppl 1):S34.
10. Riethmueller J, Ballmann M, Schroeter TW, Franke P, von Butler R, Claass A, et al.Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection 2009;37(5):424-31. [CFGD Register: PI154f].
11. Riethmueller J, Junge S, Schroeter TW, Kuemmerer K, Franke P, Ballmann M, et al.Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 2009;37(5):418-23. [CFGD Register: PI154e].
12. Semykin SY, Polikarpova SV, Dubovik LG, Kashirskaya NY. Efficiency of the inhalational tobramycin therapy in complex antibacterial therapy of lung exacerbation in cystic fibrosis children with chronic pseudomonas aeruginosa infection [abstract]. Journal of Cystic Fibrosis 2010;9 Supplement 1:S55, Abstract no: 214. [CFGD Register: PI246].
13. Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, et al.Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005;366(9484):463-71.
14. Accurso FJ. Early pulmonary disease in cystic fibrosis. Current Opinion in Pulmonary Medicine 1997;3(6):400-3.
15. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310(6994):1571-2.
16. Balaguer A, González de Dios J. Home intravenous antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD001917.pub2].
17. Beaudry PH, Marks MI, McDougall D, Desmond K, Rangel R. Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?. Journal of Pediatrics 1980;97(1):144-7.
18. Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?. Journal of Antimicrobial Chemotherapy 2006;58(4):822-9.
19. Cystic Fibrosis Foundation. Microbiology and Infectious disease in cystic fibrosis. Consensus Conference, Bethesda 1994; Vol. V (Section 1):1-26.
20. Cystic Fibrosis Foundation. National Patient Registry. Annual Data Report 2000 [Bethesda, Maryland] 2001.
21. UK Cystic Fibrosis Trust Antibiotic Group. Antibiotic treatment for Cystic Fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic Group. 3rd 2009.
22. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al.Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348(9041):1596-7.
23. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. Journal of Clinical Epidemiology 1995;48(8):1041-9.
24. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. European Respiratory Journal 2007;29(3):522-6.
25. Donaldson SH, Boucher RC. Update on pathogenesis of cystic fibrosis lung disease. Current Opinion in Pulmonary Medicine 2003;9(6):486-91.
26. Doring G, Conway SP, Heijerman HGM, Hodson ME, Hoiby N, Smyth A, et al.Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. European Respiratory Journal 2000;16(4):749-67.
27. Döring G, Flume P, Heijerman H, Elborn JS, Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. Journal of Cystic Fibrosis 2012;11(6):461-79.
28. Edenborough FP, Stone HR, Kelly SJ, Zadik P, Doherty CJ, Govan JR. Genotyping of Pseudomonas aeruginosa in cystic fibrosis suggests need for segregation. Journal of Cystic Fibrosis 2004;3(1):37-44.
29. Elborn JS. Difficult bacteria, antibiotic resistance and transmissibility in cystic fibrosis. Thorax 2004;59(11):914-5.
30. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
31. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson R L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatric Pulmonology 2002;34(2):91-100.
32. Frangolias DD, Mahenthiralingam E, Rae S, Raboud JM, Davidson AG, Wittmann R, et al.Burkholderia cepacia in cystic fibrosis: variable disease course. American Journal of Respiratory and Critical Care Medicine 1999;160(5 Pt 1):1572-7.
33. Gibson RL, Burns JL, Ramsey RL. Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003;168(8):918-51.
34. Gilligan PH. Microbiology of CF Lung Disease. In: Yankaskas JR, Knowles MR editor(s). Cystic Fibrosis in Adults. Philedelpia: Lippincott-Raven, 1999:93-114.
35. Gold R, Carpenter S, Heurter H, Corey M, Levison H. Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. Journal of Pediatrics December 1987;111:907-13.
36. Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas Aeruginosa airway colonisation in cystic fibrosis patients: 15 years experience. Journal of Cystic Fibrosis 2008;7(6):523-530.
37. Hentzer M, Teitzel GM, Balzer GJ, Heydorn A, Molin S, Givskov M, et al.Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. Journal of Bacteriology 2001;183(18):5395-401.
38. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
39. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
40. Hodson ME, Geddes DM. Cystic Fibrosis. 2nd Edition. Boston: Arnold, 2000.
41. Hodson ME. Treatment of cystic fibrosis in the adult. Respiration 2000;67(6):595-607.
42. Hoogkamp-Korstanje JA, van der Laag J. Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis. Journal Antimicrobial Chemotherapy 1983;12(2):175-83.
43. Horre R, Schaal KP, Siekmeier R, Sterzik B, de Hoog GS, Schnitzler N. Isolation of fungi, especially Exophiala dermatitidis, in patients suffering from cystic fibrosis. A prospective study. Respiration 2004;71(4):360-6.
44. Hyatt AC, Chipps BE, Kumor KM, Mellits ED, Lietman PS, Rosenstein BJ. A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. Journal of Pediatrics 1981;99(2):307-14.
45. Høiby N. Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis. Paediatric Drugs 2000;2(6):451-63.
46. Jones AM, Govan JR, Doherty CJ, Dodd ME, Isalska BJ, Stanbridge TN, et al.Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001;358(9281):557-8.
47. Jones AM, Dodd ME, Doherty CJ, Govan JR, Webb AK. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 2002;57(11):924-5.
48. Koch C, Hjelt K, Pedersen SS, Jensen ET, Jensen T, Lanng S, et al.Retrospective clinical study of hypersensitivity reactions to astreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple antibiotic courses. Reviews of Infectious Diseases 1991;13(Suppl 7):S608-11.
49. Kosorok MR, Wei WH, Farrell PM. The incidence of cystic fibrosis. Statistics in Medicine 1996;15(5):449-62.
50. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006;73(1):27-33.
51. Master V, Roberts GW, Coulthard KP, Baghurst PA, Martin A, Roberts ME, et al.Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Pediatric Pulmonology 2001;31(5):367-76.
52. McLaughlin FJ, Matthew WJ, Strieder DJ, Goldman DA. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbation of cystic fibrosis: Ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. Journal of Infectious Diseases 1983;147(3):559-67.
53. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. American Review of Respiratory Disease 1985;132(4):761-5.
54. Olesen HV, Nielsen LP, Schiotz PO. Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic. Pediatric Pulmonology 2006;41(12):1197-204.
55. Parmar JS, Nasser S. Antibiotic allergy in cystic fibrosis. Thorax 2005;60(6):517-20.
56. Penketh AR, Hodson ME, Batten JC. Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection in cystic fibrosis. British journal of diseases of the chest 1983;77(2):179-84.
57. Penketh A, Hodson ME, Gaya H, Batten JC. Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis. Thorax 1984;39(4):299-304.
58. Penketh AR, Wise A, Mearns MB, Hodson ME, Batten JC. Cystic fibrosis in adolescents and adults. Thorax 1987;42(7):526-32.
59. Petersen NT, Hoiby N, Mordhorst CH, Lind K, Flensborg EW, Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma - possible synergism with Pseudomonas aeruginosa. Acta Paediatrica Scandinavica 1981;70(5):623-8.
60. Rabin HR, Butler SM, Wohl MEB, Geller DE, Colin AA, Schidlow DV, et al.Pulmonary exacerbation in cystic fibrosis. Pediatric Pulmonology 2004;37(5):400-6.
61. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. New England Journal of Medicine 1996;335(3):179-88.
62. Rosenberg SM, Schramm CM. Predictive value of pulmonary function testing during pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology 1993;16(4):227-35.
63. Schaedel C, de Monestrol I, Hjelte L, Johannesson M, Kornfalt R, Lindblad A, et al.Predictors of deterioration of lung function in cystic fibrosis. Pediatric Pulmonology 2002;33(6):483-91.
64. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al.Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial. Lancet 2005;365(9459):573-8.
65. Starner TD, McCray PB Jr, American College of Physicians, American Physiological Society. Pathogenesis of early lung disease in cystic fibrosis: A window of opportunity to eradicate bacteria. Annals of Internal Medicine 2005;143(11):816-22.
66. Stuart B, Lin JH, Mogayzel Jr PJ. Early eradication of Pseudomonas Aeruginosa in Patients with Cystic Fibrosis. Review Article. Peadiatric Respiratory Reviews 2010;11(3):117-184.
67. Vic P, Ategbo S, Turck D, Husson MO, Launay V, Loeuille GA, et al.Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Archives of Disease in Childhood 1998;78(6):533-9.
68. Wat D. Impact of respiratory viral infections on cystic fibrosis. Postgraduate Medical Journal 2003;79(930):201-3.
69. Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD006682.pub3].